201 related articles for article (PubMed ID: 28845514)
1. Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
Miyata Y; Nakamura Y; Yasuda T; Matsuo T; Ohba K; Furusato B; Fukuoka J; Sakai H
Prostate; 2017 Oct; 77(14):1408-1415. PubMed ID: 28845514
[TBL] [Abstract][Full Text] [Related]
2. Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo-Adjuvant Hormonal Therapy in Prostate Cancer Patients.
Asai A; Miyata Y; Matsuo T; Shida Y; Hakariya T; Ohba K; Sakai H
Prostate; 2017 Feb; 77(3):255-262. PubMed ID: 27527525
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy.
Pu XY; Wang XH; Wu YL; Wang HP
J Cancer Res Clin Oncol; 2007 Aug; 133(8):555-62. PubMed ID: 17457611
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
[TBL] [Abstract][Full Text] [Related]
5. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Albersen M; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Moris L; Battaglia A; van der Poel H; Walz J; Bossi A; De Meerleer G; Haustermans K; Van Poppel H; Spahn M; Joniau S
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):407-412. PubMed ID: 28485390
[TBL] [Abstract][Full Text] [Related]
6. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy.
Stewart SB; Cheville JC; Sebo TJ; Frank I; Boorjian SA; Thompson RH; Gettman MT; Tollefson MK; Umbriet EC; Psutka SP; Bergstralh EJ; Rangel L; Karnes RJ
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):332-7. PubMed ID: 25156060
[TBL] [Abstract][Full Text] [Related]
7. Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study.
Enokida H; Yamada Y; Tatarano S; Yoshino H; Yonemori M; Sakaguchi T; Nishimura H; Eura R; Nakagawa M
Jpn J Clin Oncol; 2020 Jan; 50(1):66-72. PubMed ID: 31665352
[TBL] [Abstract][Full Text] [Related]
8. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
[TBL] [Abstract][Full Text] [Related]
9. Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy.
Miyata Y; Mitsunari K; Asai A; Takehara K; Mochizuki Y; Sakai H
Prostate; 2015 Jan; 75(1):84-91. PubMed ID: 25307287
[TBL] [Abstract][Full Text] [Related]
10. Assessments of Neoadjuvant Hormone Therapy Followed by Robotic-Assisted Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer.
Hu JC; Hung SC; Ou YC
Anticancer Res; 2017 Jun; 37(6):3143-3150. PubMed ID: 28551656
[TBL] [Abstract][Full Text] [Related]
11. Analysis of risk factors for positive surgical margin after laparoscopic radical prostatectomy with and without neoadjuvant hormonal therapy.
Wang F; Zhang G; Tang Y; Wang Y; Li J; Xing N
Front Endocrinol (Lausanne); 2023; 14():1270594. PubMed ID: 37941905
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy.
Naiki T; Kawai N; Okamura T; Nagata D; Kojima Y; Akita H; Yasui T; Tozawa K; Kohri K
BMC Urol; 2012 Dec; 12():36. PubMed ID: 23249358
[TBL] [Abstract][Full Text] [Related]
13. Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
Wang X; Qi M; Zhang J; Sun X; Guo H; Pang Y; Zhang Q; Chen X; Zhang R; Liu Z; Liu L; Hao X; Han B
Prostate; 2019 May; 79(7):709-719. PubMed ID: 30825345
[TBL] [Abstract][Full Text] [Related]
14. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
[TBL] [Abstract][Full Text] [Related]
15. Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution.
Fujita N; Koie T; Ohyama C; Tanaka Y; Soma O; Matsumoto T; Yamamoto H; Imai A; Tobisawa Y; Yoneyama T; Hatakeyama S; Hashimoto Y
Int J Clin Oncol; 2017 Dec; 22(6):1087-1093. PubMed ID: 28681153
[TBL] [Abstract][Full Text] [Related]
16. The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer.
Joung JY; Kim JE; Kim SH; Seo HK; Chung J; Park WS; Hong EK; Lee KH
BMC Urol; 2015 Aug; 15():82. PubMed ID: 26269129
[TBL] [Abstract][Full Text] [Related]
17. Clinical Analysis of Perioperative Outcomes on Neoadjuvant Hormone Therapy before Laparoscopic and Robot-Assisted Surgery for Localized High-Risk Prostate Cancer in a Chinese Cohort.
Sun G; Liang Z; Jiang Y; Ma S; Chen S; Liu R
Curr Oncol; 2022 Nov; 29(11):8668-8676. PubMed ID: 36421336
[TBL] [Abstract][Full Text] [Related]
18. Effect of Neoadjuvant Hormone Therapy on Resection Margin and Survival Prognoses in Locally Advanced Prostate Cancer after Prostatectomy Using Propensity-Score Matching.
Kim SH; Park EY; Joo J; Joung JY; Seo HK; Chung J; Lee KH
Biomed Res Int; 2018; 2018():4307207. PubMed ID: 30627554
[TBL] [Abstract][Full Text] [Related]
19. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
[TBL] [Abstract][Full Text] [Related]
20. Impact of hormonal therapy prior to radical prostatectomy on the recovery of quality of life.
Namiki S; Saito S; Tochigi T; Kuwahara M; Ioritani N; Yoshimura K; Terai A; Koinuma N; Arai Y
Int J Urol; 2005 Feb; 12(2):173-81. PubMed ID: 15733112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
